Investor Presentation First Nine Months of 2022
68
Investor presentation First nine months of 2022
Novo NordiskⓇ
In STEP 4, 41.2% of patients treated with semaglutide reached
>20% weight loss and reported improved quality of life vs placebo
Proportion of patients
Categorical weight loss
Sema 2.4 mg showed a statistically significant treatment
difference versus placebo in the SF-36 patient reported outcome
SF-36 scores
100%
90.5%
Sema 2.4 mg
Placebo
Physical functioning
80.8%
Role-physical
80%
Bodily pain
65.5%
60%
50.0%
40%
20%
H
20.9%
9.8%
41.2%
General health
Vitality
Social functioning
Role-emotional
Mental health
5.1%
Physical component summary
Mental component summary
0%
≥5%
≥10%
≥15%
≥20%
Weight loss
Descriptive statistics only. Based on the on-treatment data, i.e. data for people that are on-treatment at week 68
Sema: semaglutide
Favours placebo Favours semaglutide
-1012
ETD [95% CI]
2.46 [1.59 3.32]
*
1.44 [0.42 2.47] *
2.23 [-0.06 4.53]
1.86 [0.73: 3.00] *
4.31 [1.617.02] *
2.41 [0.07 4.76] *
1.64 [0.52: 2.76] *
2.93 [1.80 4.06] *
1.68 [0.64: 2.72] *
3.44 [2.28 4.60] *
3 4 5 6 7 8
* statistically significant; p-values other than physical functioning were not controlled for multiplicity
CI: confidence interval, ETD: estimated treatment difference, Sema: semaglutide, SF-36: Short Form (36) Health SurveyView entire presentation